AAV Manufacturing
ProBio Launches GMP AAV Manufacturing Services at Hopewell Facility to Advance Gene Therapy Development and Manufacturing
ProBio Inc
PR-08-25-NI-01Aug 11, 2025
Viral Vectors
De-Risking Cell and Gene Therapies with Innovative Solutions: A Review for Leveraging a Proven Workhorse Technology in New Ways
Farzin Farzaneh, Ph.D.; Nicholas Ostrout, Ph.D.; Glenda Dickson, Ph.D.; David Darling, Ph.D.
ViroCell Biologics
PAO-06-25-CL-12Jul 31, 2025
Viral Vectors
Backbone of Innovation: How CDMO Vector Platforms Are Accelerating Gene Therapy Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-25-NI-09Jul 21, 2025
CGT
ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility to Advance Cell and Gene Therapy
ProBio Inc
PR-06-25-NI-11Jun 30, 2025
Viral Vector CDMOs
Breaking Through the Noise in Viral Vector CDMO Marketing
Emilee Kudla
Pharma's Almanac
PAO-06-25-NI-10Jun 25, 2025
AAV
Gene Therapy at a Crossroads: Rethinking AAV Amid Industry Resets
Daniel Smith, Ph.D.
Nice Consulting
PAO-05-25-NI-02May 06, 2025
Nonviral Delivery
Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery using dbDNA
Lisa Caproni
Touchlight
PAO-12-24-CL-4Dec 16, 2024
AAV Quality
Improving AAV Vector Quality with In-Process Monitoring of Capsid Formation
Nathan Sweeney, Ph.D.; Hena Divanovic, M.Sc.
Rentschler Biopharma SE
PAO-11-24-CL-06Dec 02, 2024
CDMO
Innovating and Collaborating to Support Biopharma Beyond the Typical CDMO
Janet Hoogstraate, Ph.D.
NorthX Biologics
PAO-10-24-CL-07Oct 07, 2024
Gene Editing
MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing
Tom Adie, Ph.D.; Elena Stoyanova, Ph.D.
Touchlight
PAO-10-24-CL-01Sep 30, 2024
dbDNA
Revolutionizing the Genetic Medicine Landscape with Enzymatic DNA
Jill Makin
Touchlight
PAO-08-24-CL-01Aug 19, 2024
AAV
Overcoming Variability and Scaling Challenges in AAV Manufacturing
Rafal Garus
Viralgen Vector Core
PAO-08-24-CL-03Jul 22, 2024
Cell Therapy
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
Genezen
PR-07-24-NI-01Jul 02, 2024
Synthetic DNA
Transforming the Economics of AAV Manufacture While Optimizing Quality with dbDNA
Tom Merritt, Ph.D.
Touchlight
PAO-07-24-CL-01Jul 02, 2024
Cell and Gene Therapy Regulatory
Navigating Regulatory Complexity for Cell and Gene Therapies
Natasha Rivas
Genezen
PAO-04-24-CL-03Apr 12, 2024
Viral Vectors
A Viral Vector CDMO Vision that Resonates
Drew Brennan; Chris Berger; Elie Hanania, Ph.D.; Dave Ingamells; Rami Barghout, PE
Avid Bioservices
PAO-03-24-CL-06Mar 14, 2024
Plasmid Manufacturing
Optimizing Plasmid Production to Meet Growing Demand
Cynthia A. Challener, Ph.D.; Danielle Alvarez
Pharma's Almanac
PAO-04-23-NI-01Apr 03, 2023
Viral Vector Manufacturing
Considerations in Viral Vector Analytical Development to Enable Smooth Transfer to Quality Control
Chris Berger; Kilian Witzel
Avid Bioservices
PAO-02-23-CL-03Mar 14, 2023
AAV Capsid Engineering
Expanding Patient Access to Gene Therapies through AAV Capsid Engineering
Damien Marsic, Ph.D.
Porton Advanced Solutions
PAO-01-23-CL-02-155Feb 06, 2023
Viral Vector Manufacturing
Optimizing Transient Transfection for Viral Vector Production
Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.
Pharma's Almanac
PAO-11-022-NI-09Nov 15, 2022